Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Comment by nieroda123on Jun 18, 2014 11:01am

153 Views

Post# 22670806

RE:news on isotretinoin

Great article thanks Dave. I am interested to see further updates and possible advancements from the health care investors conference today. Growing Absorica is great but I can only penetrate new markets for so long. I would like to see management start looking for accretive aquistitions because a one trick pony is not a horse. Furthermore, I would like to hear an update on the other two drugs that are in their infancy. Hopefully this conference will help shareholders grasp a view of managements intentions. Long DND.

Bullboard Posts

Canadian artificial intelligence ETFs